Keytruda (pembrolizumab)

Numéro de dossier de l’APP: 21788
État des négociations:
Concluded with an LOI
Indication(s):
First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients
Promoteur/fabricant:
Merck Canada Inc.
Numéro de projet de l’ACMTS:
PC0250
Lettre-contrat de l’APP:
Conclusion du processus de négociation: